biopharmaceutical development / technology solutions / biotechnology / site-specific conjugation technologies / protein re-engineering technologies / pharmaceutical / biopharmaceutical products / life sciences technology / /
Organization
Board of Directors of OBN / OBN / OBN Board of Directors London / UK BioIndustry Association / Invesco Perpetual / Mercia Fund Management / Advantage Enterprise & Innovation Fund / /
Person
Mark Swallow / Sita Shah / John Burt / Chris Gardner / Donna Hackett / Sally Waterman / / /
Position
VP Intellectual Property / Commercial and Legal Affairs / VP Intellectual Property / executive director / nonexecutive director / Chief Operating Officer and executive director / Senior VP Corporate Development / CEO / Assistant Director / VP Corporate Development / COO / director of Stealthyx Therapeutics / director of Stabilitech / VP Intellectual Property / Commercial and Legal Affairs / board member / /
Region
Golden Triangle / /
Technology
biotechnology / protein re-engineering technologies / commercialising life sciences technology / biopharmaceuticals / site-specific conjugation technologies / /
PolyTherics Strengthens Management Team with Appointment of Donna Hackett as VP Intellectual Property, Commercial and Legal Affairs Sally Waterman Appointed to the OBN Board of Directors London, UK, 18 February 2014 –